Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/calico.md — the filesystem corpus, unchanged. Not an edit.
11.7 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["aging", "biotech", "drug discovery", "comparative biology", "google", "research institutes"]tags: ["aging", "biotech", "drug discovery", "comparative biology", "google", "research institutes"]summary: "Alphabet's independent biotechnology company, founded in 2013 to study the biology of aging and develop interventions against age-related disease."summary: "Alphabet's independent biotechnology company, founded in 2013 to study the biology of aging and develop interventions against age-related disease."updated: "2026-07-27"updated: "2026-10-29"issues: ["The AbbVie funding totals and the reported narrowing of the partnership carry no source."]issues: ["The AbbVie funding totals and the reported narrowing of the partnership carry no source."]------ lines 26–38 → 26–3812 unchanged lines not shown
}}`````` **Calico Life Sciences**, originally the California Life Company, is a biotechnology company founded by Google in September 2013 to study the biology of aging and translate it into treatments for age-related disease. It was the first attempt by a large technology company to fund aging research at pharmaceutical scale, it operates with unusual secrecy, and after more than a decade its public output remains modest relative to the capital committed. It is the reference case, cited both by supporters and critics, for what happens when the [[geroscience-hypothesis]] is given a large budget and a long horizon.**Calico Life Sciences**, originally the California Life Company, is a biotechnology company founded by Google in September 2013 to study the biology of aging and translate it into treatments for age-related disease. It was the first attempt by a large technology company to fund aging research at pharmaceutical scale, it operates with unusual secrecy, and after more than a decade its public output remains modest relative to the capital committed. Supporters and critics alike cite it as the reference case for what happens when the [[geroscience-hypothesis]] is given a large budget and a long horizon. ## Overview## Overview Calico's founding proposition was that aging is a tractable biological problem that pharmaceutical companies neglect because it is not a disease with a regulatory pathway, and that a company insulated from quarterly pressure could do the basic biology first and find the drug later. Arthur Levinson, formerly chief executive of Genentech and chairman of Apple, was named chief executive at launch and has held the role since.Calico's founding proposition was that aging is a tractable biological problem that pharmaceutical companies neglect because it is not a disease with a regulatory pathway, and that a company insulated from quarterly pressure could do the basic biology first and find the drug later. Arthur Levinson, formerly chief executive of Genentech and chairman of Apple, was named chief executive at launch and has held the role since. The company divides its work between discovery research — comparative biology, cellular aging mechanisms, computational genomics — and a drug development organization run in partnership with AbbVie. The two halves are connected loosely enough that Calico's most advanced clinical assets do not obviously derive from its aging research.The company divides its work between discovery research (comparative biology, cellular aging mechanisms, computational genomics) and a drug development organization run in partnership with AbbVie. The two halves are connected loosely enough that Calico's most advanced clinical assets do not obviously derive from its aging research. ## History## History lines 47–53 → 47–538 unchanged lines not shown
{ "year": "2018", "title": "Naked mole-rat mortality", "text": "Calico researchers publish evidence that naked mole-rat mortality risk does not rise measurably with age, an unusual departure from the Gompertz pattern." }, { "year": "2018", "title": "Naked mole-rat mortality", "text": "Calico researchers publish evidence that naked mole-rat mortality risk does not rise measurably with age, an unusual departure from the Gompertz pattern." }, { "year": "2018", "title": "Longevity heritability revised down", "text": "Working with Ancestry.com pedigree data, Calico scientists argue that published estimates of the heritability of human lifespan are inflated by assortative mating." }, { "year": "2018", "title": "Longevity heritability revised down", "text": "Working with Ancestry.com pedigree data, Calico scientists argue that published estimates of the heritability of human lifespan are inflated by assortative mating." }, { "year": "2020s", "title": "Clinical entry", "text": "An eIF2B activator developed with AbbVie enters trials in amyotrophic lateral sclerosis and a rare leukodystrophy, becoming the partnership's most advanced asset." }, { "year": "2020s", "title": "Clinical entry", "text": "An eIF2B activator developed with AbbVie enters trials in amyotrophic lateral sclerosis and a rare leukodystrophy, becoming the partnership's most advanced asset." }, { "year": "2023–2025", "title": "Partnership narrowed", "text": "Reports describe the collaboration being scaled back in scope as programmes are prioritized, with Calico's focus adjusting accordingly." } { "year": "2023-2025", "title": "Partnership narrowed", "text": "Reports describe the collaboration being scaled back in scope as programmes are prioritized, with Calico's focus adjusting accordingly." }]]`````` lines 55–71 → 55–711 unchanged line not shown
### Comparative biology### Comparative biology Calico recruited Rochelle Buffenstein and her naked mole-rat colony, one of the largest anywhere. The colony produced the field's most-cited quantitative claim about [[negligible-senescence]]: an analysis of thousands of animal-years finding that the hazard of death in naked mole-rats does not increase detectably with age after sexual maturity, in contrast to the Gompertzian doubling seen in nearly every other mammal.[^ruby2018] The result does not mean the animals are immortal — they die of infection, injury and, rarely, cancer — but it establishes that mammalian mortality acceleration is not obligatory.Calico recruited Rochelle Buffenstein and her naked mole-rat colony, one of the largest anywhere. The colony produced the field's most-cited quantitative claim about [[negligible-senescence]]. An analysis of thousands of animal-years found that the hazard of death in naked mole-rats does not increase detectably with age after sexual maturity, in contrast to the Gompertzian doubling seen in nearly every other mammal.[^ruby2018] The animals are not immortal, since they die of infection, injury and, rarely, cancer, but the result establishes that mammalian mortality acceleration is not obligatory. The company has also worked on the short-lived African turquoise killifish as a vertebrate aging model, and on yeast under Botstein. Comparative work of this kind is the main route by which the field learns which of the [[cellular-senescence|damage mechanisms]] observed in laboratory mice are general features of mammalian aging and which are artefacts of one heavily inbred species with a three-year lifespan.The company has also worked on the short-lived African turquoise killifish as a vertebrate aging model, and on yeast under Botstein. Comparative work of this kind is the field's main way of learning which of the [[cellular-senescence|damage mechanisms]] observed in laboratory mice are general features of mammalian aging and which are artefacts of one heavily inbred species with a three-year lifespan. ### Human genetics### Human genetics A Calico collaboration with Ancestry.com analysed pedigree data from hundreds of millions of individuals and concluded that published heritability estimates for human lifespan — commonly given as roughly 25 per cent — are substantially inflated because people choose partners with similar life expectancy, which pedigree methods misattribute to genetics.[^ruby2018b] The corrected estimate was well under 10 per cent. This is one of the field's more consequential negative results, and it constrains what genomic approaches to [[maximum-human-lifespan]] can be expected to deliver. The estimate is a population average; the centenarian-genetics programmes run by [[nir-barzilai]] and others instead look for variants in exceptionally long-lived families.A Calico collaboration with Ancestry.com analysed pedigree data from hundreds of millions of individuals and concluded that published heritability estimates for human lifespan, commonly given as roughly 25 per cent, are substantially inflated. People choose partners with similar life expectancy, and pedigree methods misattribute that similarity to genetics.[^ruby2018b] The corrected estimate was well under 10 per cent. It is one of the field's more consequential negative results, and it constrains what genomic approaches to [[maximum-human-lifespan]] can be expected to deliver. The estimate is a population average; the centenarian-genetics programmes run by [[nir-barzilai]] and others instead look for variants in exceptionally long-lived families. ### Drug programmes### Drug programmes Calico's most advanced clinical asset with AbbVie is a small-molecule activator of eIF2B, the translation-initiation factor whose inhibition drives the integrated stress response. It has been studied in amyotrophic lateral sclerosis and in vanishing white matter disease, a rare leukodystrophy caused by eIF2B mutations. Other disclosed programmes have included work on [[proteostasis]] and on cancer immunology. None is an aging indication, because no such indication exists at any regulator — the problem the [[metformin|TAME trial]] was designed to address.Calico's most advanced clinical asset with AbbVie is a small-molecule activator of eIF2B, the translation-initiation factor whose inhibition drives the integrated stress response. It has been studied in amyotrophic lateral sclerosis and in vanishing white matter disease, a rare leukodystrophy caused by eIF2B mutations. Other disclosed programmes have included work on [[proteostasis]] and on cancer immunology. None is an aging indication, because no such indication exists at any regulator, which is the problem the [[metformin|TAME trial]] was designed to address. > [!key] Why the pipeline is not about aging> [!key] Why the pipeline is not about aging> A company cannot run a registrational trial for "aging" because no regulator recognizes it as a treatable condition and no [[aging-biomarkers|surrogate endpoint]] has been qualified. Every well-capitalized longevity company therefore ends up developing drugs for specific diseases and arguing that the underlying biology generalizes. One route around the constraint has been veterinary: [[loyal]] is pursuing a lifespan indication in dogs, which the animal-drug regulator will entertain and its human counterpart will not. Calico's pipeline is the clearest illustration of the constraint.> A company cannot run a registrational trial for "aging" because no regulator recognizes it as a treatable condition and no [[aging-biomarkers|surrogate endpoint]] has been qualified. Every well-capitalized longevity company therefore ends up developing drugs for specific diseases and arguing that the underlying biology generalizes. One route around the constraint has been veterinary: [[loyal]] is pursuing a lifespan indication in dogs, which the animal-drug regulator will entertain and its human counterpart will not. Calico's pipeline is the clearest illustration of the constraint.lines 74–94 → 74–942 unchanged lines not shown
Calico is a subsidiary of Alphabet and does not publish financial statements. Alphabet's filings have disclosed its holdings in the "Other Bets" segment without breaking out Calico specifically. Public estimates of total commitment from Alphabet and AbbVie combined run to several billion dollars over a decade, which places it in the same order of magnitude as Altos Labs.Calico is a subsidiary of Alphabet and does not publish financial statements. Alphabet's filings have disclosed its holdings in the "Other Bets" segment without breaking out Calico specifically. Public estimates of total commitment from Alphabet and AbbVie combined run to several billion dollars over a decade, which places it in the same order of magnitude as Altos Labs. Its structure is unusual in a way that cuts both directions. Independence from Alphabet's core business gave it a long horizon; dependence on AbbVie for development gave it a partner whose priorities are pharmaceutical rather than gerontological, and when those priorities shifted the collaboration narrowed accordingly.Its structure has cut both ways. Independence from Alphabet's core business gave it a long horizon. Dependence on AbbVie for development gave it a partner whose priorities are pharmaceutical rather than gerontological, and when those priorities shifted the collaboration narrowed accordingly. ## Reception## Reception Criticism of Calico centres on output. For a decade of work at pharmaceutical scale the public record consists of a respectable but not extraordinary body of papers, no approved drug, and no aging-specific programme. Researchers in the field have noted that the secrecy makes it impossible to distinguish between slow progress and undisclosed progress, and that a company drawing heavily on academic talent while publishing selectively imposes a cost on the field it does not repay.Criticism of Calico centres on output. For a decade of work at pharmaceutical scale the public record consists of a respectable but not extraordinary body of papers, no approved drug, and no aging-specific programme. Researchers in the field have noted that the secrecy makes it impossible to distinguish between slow progress and undisclosed progress, and that a company drawing heavily on academic talent while publishing selectively imposes a cost on the field it does not repay. A more sympathetic reading is that Calico did exactly what it said it would. It funded basic biology for years without a product, produced at least two results — the naked mole-rat mortality analysis and the heritability correction — that changed what specialists believe, and reached the clinic with a mechanism-driven drug. Measured against the founding rhetoric about solving death it has failed; measured against a realistic prior for a preclinical research organization, it is unremarkable in both directions. Nothing it has produced has been shown to match the benefit of [[exercise-and-aging|exercise]], which remains the comparator any candidate geroprotector has to beat, and it has not attempted the kind of repurposing trial that [[rapamycin]] and [[senolytics]] advocates have pursued with far less money.A more sympathetic reading is that Calico did exactly what it said it would. It funded basic biology for years without a product, produced at least two results that changed what specialists believe (the naked mole-rat mortality analysis and the heritability correction), and reached the clinic with a mechanism-driven drug. Measured against the founding rhetoric about solving death, it has failed. Measured against a realistic prior for a preclinical research organization, it is unremarkable in both directions. Nothing it has produced has been shown to match the benefit of [[exercise-and-aging|exercise]], which remains the comparator any candidate geroprotector has to beat, and it has not attempted the kind of repurposing trial that [[rapamycin]] and [[senolytics]] advocates have pursued with far less money. The company also serves as a cautionary reference for the [[longevity-dividend]] argument. Money and time have been supplied at a level the field had never previously seen, and the constraint that bound was not funding but the absence of a validated target and a measurable endpoint.The company is also a cautionary reference for the [[longevity-dividend]] argument. Money and time were supplied at a level the field had never previously seen, and the binding constraint turned out to be the absence of a validated target and a measurable endpoint rather than funding. ## Outlook## Outlook The signals worth watching are whether the eIF2B programme produces a positive phase-three result in ALS, which would validate the discovery organization independently of aging; whether Calico discloses a programme aimed at one of the [[hallmarks-of-aging]] as revised in 2023 rather than at a named disease;[^lopez2023] and whether Alphabet's commitment survives the narrowing of the AbbVie relationship.The signals worth watching are whether the eIF2B programme produces a positive phase-three result in ALS, which would validate the discovery organization independently of aging; whether Calico discloses a programme aimed at one of the [[hallmarks-of-aging]] as revised in 2023 rather than at a named disease;[^lopez2023] and whether Alphabet's commitment survives the narrowing of the AbbVie relationship. The larger question Calico poses is not about Calico. If more than a decade of well-funded, competently run work on the biology of aging has not produced a candidate intervention against aging itself, the constraint is unlikely to be money, and the field's assumption that scale was the missing ingredient — an assumption [[retro-biosciences]], [[newlimit]] and Altos are all now testing again with fresh capital — needs a better justification than it currently has.Calico's record also bears on the field as a whole. If more than a decade of well-funded, competently run work on the biology of aging has not produced a candidate intervention against aging itself, the constraint is unlikely to be money. The field's assumption that scale was the missing ingredient, which [[retro-biosciences]], [[newlimit]] and Altos are all now testing again with fresh capital, needs a better justification than it currently has. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
97 lines are the same in both revisions, and 44 of them are not shown. Neither revision here is necessarily the current article — read Calico Life Sciences for the text this wiki stands behind today.